Abiopharma

🔍 Grant-Huerta Yanina (Executive)

Company: ImageneBio, Inc. (IMA)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Acquired 65,000 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 65,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 39,000 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 104,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 56,000 shares of Employee Stock Option (right to buy) at $5.84 per share (Derivative)
  Date: 2026-08-14 | Code: A | Expires: 2036-08-13 | equity_swap_involved: 0 | shares_owned_after: 56,000.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: On July 23, 2026, the Issuer filed a Current Report on Form 8-K reporting that the Reporting Person was entitled to receive pursuant to her employment offer letter 65,000 restricted stock units ("RSUs") and 95,000 stock options. It was subsequently determined that in lieu of the foregoing grants which had not yet been made, the Reporting Person would receive 104,000 restricted stock units in the aggregate and 56,000 options (the "Options"). These updated awards were granted on August 14, 2026 and are reported herein.
• F2: Represents the number of shares of the Issuer's Common Stock underlying RSUs. Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on July 20, 2027, and the remaining RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
• F3: The Options vest over four years, with 25% of the shares vesting on July 20, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.